Full text
Earnings transcript
Read the complete earnings call transcript.
TLRY
Tilray Brands, Inc.
$3.99
0.05
(1.27%)
| Exchange: | NASDAQ |
| Market Cap: | 446.208M |
| Shares Outstanding: | 2.308M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Irwin David Simon | |||||
| Full Time Employees: | 3595 | |||||
| Address: |
| |||||
| Website: | https://www.tilray.com |
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray’s portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
Click to read more…
Revenue Segmentation
TLRY full analysis
YouTube Video Transcript: Comprehensive Stock Analysis of Tilray Brands, Inc. (TLRY) Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive stock analysis of Tilray Brands, Inc., ticker symbol TLRY, a major player in the cannabis and consumer packaged goods space. If you’re interested in the cannabis industry or looking for the next big investment opportunity, you’re in the right place. We’re going to cover everything from their financials to recent performance, valuation, and even an…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 1,074,988.700 | 1,126,991.996 | 915,454 |
| Gross Profit | 304,331.372 | 330,107.748 | 260,441 |
| EBITDA | -99,253.686 | -2,919,405.578 | -38,563 |
| Operating Income | -238,102.294 | -3,132,304.973 | -63,027 |
| Net Income | -333,803.761 | -3,000,620.016 | -122,567 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 4,221,665 | 2,074,327 | 2,328,012 |
| Total Liabilities | 778,487 | 584,752 | 733,145 |
| Total Stockholders Equity | 3,442,906 | 1,511,474 | 1,614,332 |
| Total Debt | 387,317 | 235,126 | 310,097 |
| Cash and Cash Equivalents | 228,340 | 221,666 | 225,977 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | -30,905 | -94,599 | -69,144 |
| Capital Expenditure | -29,249 | 0 | 0 |
| Free Cash Flow | -60,154 | -94,599 | -69,144 |
| Net Income | -222,404 | -2,181,356 | -105,158 |
| Net Change in Cash | 21,708 | -6,674 | 7,676 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,173,432.567 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,406,400.397 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,345,700 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 154,597.037 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 171,163.800 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 166,847.637 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 48,474.861 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 61,562.604 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 58,152.835 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 398,020.532 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 477,041.673 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 456,452.501 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 0.520 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 0.550 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 0.430 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 2 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Record Revenue Growth: Tilray Brands reported a record Q2 FY2026 net revenue of $218 million, reflecting strong top-line performance and operational scalability. This growth aligns with the company's focus on diversified product offerings across cannabis, beverages, and wellness segments.
- Operational Efficiency and Innovation: The Q2 FY2026 earnings call highlighted a commitment to enhancing operational efficiency and product innovation, which supports sustained growth and competitiveness within the cannabis and related industries.
- Diversified Portfolio: The company's revenue product segments indicate a balanced approach across multiple categories, reducing reliance on a single revenue stream and providing resilience against market fluctuations.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about TLRY valuation
Is Tilray Brands, Inc. (TLRY) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Tilray Brands, Inc. (TLRY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TLRY a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TLRY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TLRY’s P/E ratio?
You can see TLRY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TLRY?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TLRY a good long-term investment?
Whether TLRY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TLRY
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.27
Trading Metrics:
| Open: | 3.99 | Previous Close: | 3.94 | |
| Day Low: | 3.92 | Day High: | 4 | |
| Year Low: | 3.67 | Year High: | 23.2 | |
| Price Avg 50: | 4.4 | Price Avg 200: | 6.42 | |
| Volume: | 3.09M | Average Volume: | 3.861M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
